Psycho-Babble Medication Thread 1024303

Shown: posts 1 to 11 of 11. This is the beginning of the thread.

 

SLS Minocycline evidence!

Posted by Slabicki on August 27, 2012, at 17:42:56

Hi Scott,

I was just going to ask what medical evidence did
you present to your Pdoc?
I just had a print out from the link that Philippa
posted.
I don't think that the evidence from the clinical drug trials will be convincing enough.
But I've tried before such exotic drugs as Riluzole, Baclofen and Marinol, and also Captopril.
All of them saved me and my job in the past.
OMG! I'm just going crazy now.
I will find out my results tomorrow.
I just have to hang in there for now!

Slabicki

 

Re: SLS Minocycline evidence! » Slabicki

Posted by SLS on August 27, 2012, at 18:34:52

In reply to SLS Minocycline evidence!, posted by Slabicki on August 27, 2012, at 17:42:56

BMJ Open. 2012 Feb 22;2(1):e000643. Print 2012.
Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial.
Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W.
Source

Laureate Institute for Brain Research (LIBR), Tulsa, Oklahoma, USA.
Abstract

INTRODUCTION: New medication classes are needed to improve treatment effectiveness in the depressed phase of bipolar disorder (BD). Extant evidence suggests that BD is characterised by neural changes such as dendritic remodelling and glial and neuronal cell loss. These changes have been hypothesised to result from chronic inflammation. The principal aims of the proposed research is to evaluate the antidepressant efficacy in bipolar depression of minocycline, a drug with neuroprotective and immune-modulating properties, and of aspirin, at doses expected to selectively inhibit cyclooxygenase 1 (COX-1). METHODS AND ANALYSIS: 120 outpatients between 18 and 55 years of age, who meet DSM-IV-TR criteria for BD (type I or II) and for a current major depressive episode will be recruited to take part in a randomised, double-blind, placebo-controlled, parallel-group, proof-of-concept clinical trial following a 2×2 design. As adjuncts to existing treatment, subjects will be randomised to receive one of the four treatment combinations: placebo-minocycline plus placebo-aspirin, active-minocycline plus placebo-aspirin, placebo-minocycline plus active-aspirin or active-minocycline plus active-aspirin. The dose of minocycline and aspirin is 100 mg twice daily and 81 mg twice daily, respectively. Antidepressant response will be evaluated by assessing changes in the Montgomery-Asberg Depression Rating Scale scores between baseline and the end of the 6-week trial. As secondary outcome measures, the anti-inflammatory effects of minocycline and aspirin will be tested by measuring pre-treatment and post-treatment levels of C reactive protein and inflammatory cytokines. ETHICS AND DISSEMINATION: Minocycline has been widely used as an antibiotic in doses up to 400 mg/day. Low-dose aspirin has been safely used on a worldwide scale for its role as an antithrombotic and thrombolytic. The study progress will be overseen by a Data, Safety and Monitoring Board, which will meet once every 6 months. Results of the study will be published in peer-reviewed publications. TRIAL REGISTRATION NUMBER: Clinical Trials.gov: NCT01429272.

PMID:
22357572
[PubMed - in process]
PMCID:
PMC3289990

Free PMC Article
Related citations
Icon for HighWire Press Icon for PubMed Central

2.
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jun 1;37(2):222-6. Epub 2012 Feb 10.
Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study.
Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, Tsuchie K, Taki M, Ishihara K, Araki T, Horiguchi J.
Source

Department of Psychiatry, Shimane University School of Medicine, Izumo, Japan. miyanyan@med.shimane-u.ac.jp
Abstract
BACKGROUND:

Approximately 25% of patients admitted to a hospital as a result of depression are actually suffering from psychotic depression. Psychotic symptoms can be present in patients with either unipolar depression or bipolar depression and can be difficult to treat. It was reported the second-generation tetracycline may exert potential antidepressant effects through its robust neuroprotective activities, which include neurogenesis, antioxidation, and anti-glutamate excitotoxicity, and may direct regulation of pro-inflammatory agents.
METHODS:

This was a 6-week, open-label study to evaluate the efficacy and safety of minocycline in combination with antidepressants in adult inpatients (n=25) diagnosed with major depression with psychotic features (psychotic depression) according to DSM-IV-TR. The primary endpoint was the change from baseline in the Hamilton Depression Rating Scale (HAM-D-21) score from baseline to week 6. Secondary endpoints were changes in the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression (CGI) Scale scores from baseline to week 6. Spontaneously reported adverse events were recorded.
RESULTS:

The patients' average age was 46.9±10.2 years. Minocyline (150 mg/day) in combination with antidepressants (fulvoxamine, paroxetine, and sertraline) provided significant improvement in depression. Mean (± SD) HAM-D-21 was reduced to 6.7±1.9 at week 6 from a baseline value of 40.4±2.5. Significant improvement of psychotic symptoms (mean±SD) was indicated by the decrease in BPRS scores from baseline (63.3±8.7) to week 6 (4.6±2.4). No serious adverse events occurred.
CONCLUSIONS:

These preliminary data suggest that minocycline in combination with antidepressants is effective and well tolerated in the treatment of unipolar psychotic depression. Further studies using larger, double-blind, parallel-group design are warranted to confirm these findings.

Copyright © 2012 Elsevier Inc. All rights reserved.

PMID:
22349578
[PubMed - indexed for MEDLINE]

Related citations
Icon for Elsevier Science
Publication Types, MeSH Terms, Substances

3.
Brain Res Rev. 2009 Oct;61(2):105-23. Epub 2009 May 28.
Emerging role of glutamate in the pathophysiology of major depressive disorder.
Hashimoto K.
Source

Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan. hashimoto@faculty.chiba-u.jp
Abstract

Major depressive disorder (MDD) is a common, chronic, recurrent mental illness that affects millions of individuals worldwide. To date, the monoaminergic systems (serotonin, norepinephrine, and dopamine) have received the most attention in the neurobiology of MDD, and all classes of antidepressants target these monoaminergic systems. Accumulating evidence suggests that the glutamatergic system plays an important role in the neurobiology and treatment of this disease. Some clinical studies have demonstrated that the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid antidepressant effects in treatment-resistant patients with MDD. Here, the author reviews the recent findings on the role of the glutamatergic system in the neurobiology of MDD and in new potential therapeutic targets (NMDA receptors, AMPA receptors, metabotropic glutamate receptors, ceftriaxone, minocycline, N-acetyl-L-cysteine) for MDD.

PMID:
19481572
[PubMed - indexed for MEDLINE]

Related citations
Icon for Elsevier Science
Publication Types, MeSH Terms, Substances

4.
Biomed Pharmacother. 2008 Jun;62(5):308-11. Epub 2008 Jan 14.
Does minocycline have antidepressant effect?
Pae CU, Marks DM, Han C, Patkar AA.
Source

Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, 505 Banpo-Dong, Seocho-Gu, Seoul 137-701, South Korea. chiun.pae@duke.edu
Abstract

Only one-third of patients undergoing monotherapy with an antidepressant achieve remission of their depressive symptoms and gain functional recovery. Therefore, further exploration of antidepressant mechanisms of action is important in order to facilitate the development of antidepressants with new modes of action. Preclinical and clinical studies have demonstrated that major depression is associated with impaired inflammatory responses and deficient neuroprotection. In this regard, we propose that the second-generation tetracycline "minocycline" may hold a potential as a new treatment for major depression. Emerging findings in animal and human studies of minocycline reveal that it has antidepressant-like neuroprotective and anti-inflammatory actions, and minocycline has been shown to perform as an antidepressant in an accepted animal model (forced swimming test). Anecdotal evidence supports minocycline's efficacy for augmentation of antidepressants in major depressive disorder. The following review describes the evidence supporting the consideration of minocycline as a potential antidepressant. We suggest that minocycline may be particularly helpful in patients with depression and comorbid cognitive impairment, as well as depression associated with organic brain disease. We also describe the antinociceptive effect of minocycline and propose a role for minocycline in the treatment of patients with major depression and prominent somatic discomfort and somatoform spectrum disorders. The lack of clinical studies of minocycline for depression is noted. Further studies of the potential therapeutic mechanism of minocycline and its therapeutic implications for major depression are warranted, and may substantially contribute to the development of newer and more effective antidepressants.

PMID:
18267354
[PubMed - indexed for MEDLINE]

Related citations
Icon for Elsevier Science
MeSH Terms, Substances

5.
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):380-6. Epub 2007 Sep 14.
Antidepressant-like actions of minocycline combined with several glutamate antagonists.
Molina-Hernández M, Tellez-Alcántara NP, Pérez-García J, Olivera-Lopez JI, Jaramillo-Jaimes MT.
Source

Laboratorio de Conducta, Instituto de Investigaciones Psicológicas, Universidad Veracruzana, Jalapa, Veracruz, México. mimolis@hotmail.com
Abstract

This study tested the potential antidepressant activity of minocycline alone or combined with two traditional antidepressant drugs or several glutamate receptor antagonists, using the time sampling method in the forced swimming test. Results showed that: desipramine (10.0 mg/kg, P<0.05; 15.0 mg/kg, P<0.05), minocycline (60.0 mg/kg, P<0.05; 80.0 mg/kg, P<0.05) and EMQMCM (1.5 mg/kg, P<0.05; 2.0 mg/kg, P<0.05), reduced immobility by increasing climbing. Fluoxetine (20.0 mg/kg, P<0.05; 25.0 mg/kg, P<0.05) reduced immobility by increasing swimming. MTEP (5.0 mg/kg, P<0.05; 10.0 mg/kg, P<0.05) and dizolcipine (1.0 mg/kg, P<0.05; 1.5 mg/kg, P<0.05) reduced immobility by increasing swimming and climbing. Combination experiments showed that a subthreshold dose of minocycline (50.0 mg/kg) synergized the antidepressant-like actions of subthreshold doses of: desipramine (5.0 mg/kg; P<0.05), EMQMCM (0.6 mg/kg; P<0.05), MTEP (2.5 mg/kg; P<0.05) and dizolcipine (0.5 mg/kg; P<0.05). In conclusion, minocycline produced antidepressant-like actions in the FST and subthreshold dose of minocycline combined with subthreshold dose of desipramine and several glutamate receptor antagonists and produced antidepressant-like actions.

 

Re: SLS Minocycline evidence! » SLS

Posted by Phillipa on August 27, 2012, at 19:11:13

In reply to Re: SLS Minocycline evidence! » Slabicki, posted by SLS on August 27, 2012, at 18:34:52

Did you up your dose? Any changes? Still thinking of doing on own? Phillipa

 

Re: SLS Minocycline evidence! » Phillipa

Posted by SLS on August 27, 2012, at 22:31:54

In reply to Re: SLS Minocycline evidence! » SLS, posted by Phillipa on August 27, 2012, at 19:11:13

> Did you up your dose? Any changes? Still thinking of doing on own? Phillipa

I made an appointment to see my doctor next week. I will stay at 100 mg/day of minocycline until then. I would like to be taking 150 mg/day. I sent him the protocol for an ongoing study for bipolar depression that will be using 100 - 300 mg/day.

http://clinicaltrials.gov/ct2/show/NCT01514422


- Scott

 

Re: SLS Thank You!(nm) (nm)

Posted by Slabicki on August 27, 2012, at 22:56:03

In reply to Re: SLS Minocycline evidence! » Slabicki, posted by SLS on August 27, 2012, at 18:34:52

 

Re: SLS Minocycline evidence! » SLS

Posted by Phillipa on August 28, 2012, at 20:13:12

In reply to Re: SLS Minocycline evidence! » Phillipa, posted by SLS on August 27, 2012, at 22:31:54

Scott I see age as 66, having thyroid disorder, and OCD anxiety, and not tolerating the mino as exclusions on my side. Doesn't mean I can't take though. I did some further research and found that it can cause discoloration of skin and nails, and a lupus which will go away if med discontinued after approxiamately a year. I then did a comparison search for doxycycline and mino and seemed like doxy could also cross blood brain barrier. And with the dosing a bit different do same without those side effects. It does make one more sensitive to sun hence dermatologists don't prescribe during the summer. I might need this one. So still 50mg BID. And I see bipolar and a mood stabalizer are a must. Will have to see if the peioral goes away with the antibiotic creams if not get the doxy as this is the one the infection control doc said to take for the still positive lymes. Oh both are used in lymes also. It covers a broad spectum of bacterias. Phillipa

 

Re: SLS Minocycline evidence!

Posted by jono_in_adelaide on August 28, 2012, at 23:14:15

In reply to Re: SLS Minocycline evidence! » SLS, posted by Phillipa on August 28, 2012, at 20:13:12

Any of the tetracyclines would cover lymes disease, doxycycline, minocycline, tetracycline, oxytertacycline

Doctors usualy use doxy because it is well adsorbed, has a good side effect profile, only needs once daily dosing, and is cheap

 

Re: SLS Minocycline evidence!

Posted by jono_in_adelaide on August 28, 2012, at 23:17:47

In reply to Re: SLS Minocycline evidence! » SLS, posted by Phillipa on August 28, 2012, at 20:13:12

But in all honesty Phillipa, I'd think you'd be better off trying an SSRI or another antidepressant in a higher dose than you're currently taking than trying exotic remedies like minocycline.

 

Re: SLS Minocycline evidence! » jono_in_adelaide

Posted by SLS on August 29, 2012, at 4:19:40

In reply to Re: SLS Minocycline evidence!, posted by jono_in_adelaide on August 28, 2012, at 23:17:47

> But in all honesty Phillipa, I'd think you'd be better off trying an SSRI or another antidepressant in a higher dose than you're currently taking than trying exotic remedies like minocycline.


In what ways is minocycline exotic? Exotic or not, it does seem to be a remedy for unipolar and bipolar depression.

It can't be all that exotic:

http://clinicaltrials.gov/ct2/show/NCT01514422

http://clinicaltrials.gov/ct2/show/NCT01429272

http://clinicaltrials.gov/ct2/show/NCT01659320

http://clinicaltrials.gov/ct2/show/NCT01574742

http://clinicaltrials.gov/ct2/show/NCT01403662

http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01574742

http://www.clinicaltrialsgps.com/search-clinical-trials/trial-33173/?Location=72766

These are just for depression. There are a bunch for schizophrenia as well.

In the 1950s, can you imagine how exotic it was to see a drug used to treat tuberculosis act as a potent antidepressant? It turned out that this drug was an MAOI.

Although minocycline is a tetracycline derivative, it is replete with psychobiological properties not seen in the other tetracyclines.

http://www.dr-bob.org/babble/20120803/msgs/1023257.html

Minocycline would still help with depression were you to cleave off or neutralize the part of the molecule responsible for its antibiotic properties. In fact, there are people working on designing such a molecule.

http://www.dr-bob.org/babble/20120803/msgs/1023257.html


- Scott

 

Re: SLS Minocycline evidence!

Posted by jono_in_adelaide on August 29, 2012, at 18:37:58

In reply to Re: SLS Minocycline evidence! » jono_in_adelaide, posted by SLS on August 29, 2012, at 4:19:40

Its excotic in that it isnt widely uses - and as phillipa only takes the minimum daily dose of an add (50mg of fluvoxamine, which is subtheraputic for OCD) and some benzo, I feel she has a lot of main stream meds to explore yet.

Taking broad spectrum antibiotics long term isnt without dangers of its own, so I'd feel more comfortable exhausting the more traditional remedies forst. If you have tried lots of things without sucsess, of cause minocycline (or virtualy anything) would be worth a shot, I just dont get the impression that Phillipa is there yet

 

Re: SLS Minocycline evidence! » jono_in_adelaide

Posted by Phillipa on August 29, 2012, at 20:38:40

In reply to Re: SLS Minocycline evidence!, posted by jono_in_adelaide on August 29, 2012, at 18:37:58

Before babble was found by my husband had been on so many SSRI's & SNRI's even a TCA, tried serzone, remeron. Since I still test positive for lymes as was in hospital a month with pic line part of the time for recephin IV. The infection contral doc had given me doxycycline with 11 refills to take l00mg twice a day. I only stopped as was having surgery and the antibiotic for post was different. I should have resumed with the doxy but didn't much to my regret as always felt better on an antibiotic. The best was the two years of biaxin xl three months on and three months off for two years. About a month after is when lost taste and smell. I have to wonder if it was a resurgence of lymes that caused the virus in neurons of nose that caused this to happen 9 years ago. Loss Of Taste & Smell is the most depressing thing that has ever happened to me. I did better with just benzos. Not the dumb luxox yes low dose can't get off of. Another story though. Minocycline given for perioral dermatitis just caused too much dizziness & headaches. I have it here. But the dose is higher than Scott's. 75mg twice a day. Waiting to see how he does and then may resume it. Phillipa


This is the end of the thread.


Show another thread

URL of post in thread:


Psycho-Babble Medication | Extras | FAQ


[dr. bob] Dr. Bob is Robert Hsiung, MD, bob@dr-bob.org

Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.